Oryzon Genomics — KOL event highlights vafidemstat potential in BPD
At Oryzon Genomics’ key opinion leader (KOL) event, vafidemstat’s path through Phase III in borderline personality disorder (BPD) was laid out. The...
431 Views
Oryzon Genomics — A step closer to a new treatment paradigm in BPD
Oryzon Genomics has submitted the Phase III clinical trial protocol to the FDA for its lysine-specific demethylase 1 (LSD1) inhibitor, vafidemstat,...
251 Views
Oryzon Genomics — Preparations in place for an active 2025
Q125 saw Oryzon make significant headway towards Phase III for vafidemstat in BPD and clinical advancement for iadademstat across multiple...
254 Views
Oryzon Genomics — €13.3m grant improves operating headroom
Oryzon Genomics has been awarded a €13.26m (US$15m) non-dilutive grant under the Med4Cure initiative, part of the Important Project of Common...
308 Views
Oryzon Genomics — Capital raise to support long-term strategy
Oryzon has secured €30m through an equity raise (straight equity, no warrants attached) to support clinical development activities and other...
265 Views